Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model

• Bo Mi Ku ,

  Contributed equally to this work with: Bo Mi Ku, Moon Ki Choi

  Roles Investigation, Writing – original draft

  Affiliation Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  ⨯
• Moon Ki Choi ,

  Contributed equally to this work with: Bo Mi Ku, Moon Ki Choi

  Roles Investigation

  Affiliation Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea

  ⨯
• Jong-Mu Sun,

  Roles Funding acquisition, Investigation

  Affiliation Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  ⨯
• Se-Hoon Lee,

  Roles Investigation

  Affiliation Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  ⨯
• Jin Seok Ahn,

  Roles Investigation

  Affiliation Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  ⨯
• Keunchil Park,

  Roles Investigation

  Affiliation Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  ⨯
• Myung-Ju Ahn

  Roles Funding acquisition, Supervision

  * E-mail: silk.ahn@samsung.com, silkahn@skku.edu

  Affiliation Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  http://orcid.org/0000-0002-5740-9654

  ⨯